Thrombosis of the palmar digital vein after Oxford‐AstraZeneca COVID‐19 vaccination

Abstract

10 days after the onset of systemic symptoms, however, 14.7% of patients had skin lesions as their first symptom.Interestingly, our patient's cutaneous findings were the only manifestation of this viral illness. He had no history of allergy or any similar hands or feet manifestations in the past, and his RT-PCR became negative concomitantly with the resolution of the dermatological manifestations. All in all, these findings are in favor of a viral-induced skin eruption associated with COVID-19. While recognition of COVID-19 in asymptomatic or minimally symptomatic patients is challenging, it is mandatory to public health. 3,5 Therefore, dermatologists should be conscious of their role during this pandemic as skin findings can be the first and sometimes only manifestation of COVID-19.

Palmar Digital Vein Thrombosis: A Case Report and Review of 36 Cases

“…More recent possible triggers for palmar vein thrombosis include COVID-19 infection [ 7 ] and the COVID-19 vaccine. The latter was reported 8 days after vaccination with a first dose of the Oxford-AstraZeneca COVID-19 vaccine [ 10 ] .…”

“…Conservative treatment included massaging the nodule and hot compresses [ 15 ] . In the case of thrombosis secondary to hypercoagulable states, treatment also included compression bandaging [ 2 ] , aspirin [ 2 ] and rivaroxaban [ 10 ] . Surgical excision is almost always curative and considered when the lesion is causing discomfort to the patient or if the clinical diagnosis is uncertain [ 15 ] .…”

SARS‐CoV‐2 vaccine‐related cutaneous manifestations: a systematic review

“…In cases where the same sample was used for more than one study, all studies were reviewed to determine the extent to which there may be duplication in the reported outcomes between studies. The full text of selected studies was reviewed, and data on demographics, article type, number of reported cases with cutaneous involvement, vaccine, and rash type (morphology) were extracted from articles texts, tables, figures, and summarized through a descriptive table (Table 1)…”

“…), 1 Covishield (Nagrani et al106 ), 1 Moderna (Pesqu e et al154 ), 1 Pfizer (Ricardo et al168 ), 1 Pfizer (Song et al200 ) 69. ), 2 Pfizer (Gruenstein et al109 ), 1 Astrazeneca (Chen et al132 ), 1 Pfizer (Aoki et al144 ) 92. ), 1 Not specified (Dash et al115 ), 1 Pfizer (Holmes et al124 ), 1 Pfizer (Tihy et al130 ) 30.…”